Target intelligence / Profile preview

Coxiella burnetii peptide epitopes bound to Major Histocompatibility Complex (MHC) molecules (C. burnetii peptide-MHC complexes)

Target
C. burnetii peptide-MHC complexes
Molecular classification
Peptide-MHC complex, Antigenic epitope, T-cell epitope
01

Overview

Coxiella burnetii peptide epitopes bound to Major Histocompatibility Complex (MHC) molecules are essential mediators of the host adaptive immune response against Q fever (1.1.1, 1.3.3). These complexes are formed when proteins from the intracellular bacterium C. burnetii are processed by antigen-presenting cells and displayed on the cell surface for recognition by T-cell receptors (1.3.1). MHC Class I molecules present these peptides to CD8+ cytotoxic T cells, while MHC Class II molecules present them to CD4+ helper T cells, both of which are vital for the clearance of the pathogen (1.2.2, 1.3.3). In clinical settings, the effective recognition of these epitopes is associated with bacterial clearance, whereas an inadequate T-cell response can lead to persistent or chronic infection, such as endocarditis (1.2.4, 1.3.3). These peptide-MHC complexes are the primary targets for the development of novel subunit vaccines designed to elicit protective immunity without the severe reactogenicity seen with the existing whole-cell vaccine, Q-Vax (1.2.2, 1.2.3). Current research focuses on identifying promiscuous epitopes that can bind a wide range of human leukocyte antigen (HLA) alleles to ensure broad population coverage and improved diagnostic accuracy (1.2.2, 1.3.1).

Other names
Q fever epitopesCoxiella burnetii T-cell epitopesMHC-restricted C. burnetii peptidesHLA-restricted C. burnetii epitopesC. burnetii pMHC
02

Mechanism of action

Stimulation of CD4+ and CD8+ T-cell responses through T-cell receptor (TCR) recognition of the peptide-MHC complex, leading to Th1 cytokine release (e.g., IFN-gamma) and intracellular killing of the pathogen (1.2.2, 1.3.3).

03

Biological functions

Immune responseAntigen presentationT-cell activationCytokine productionBacterial clearance
04

Disease associations

InfectionQ feverChronic Q feverEndocarditis
05

Safety considerations

Reactogenicity in previously exposed or sensitized individualsHLA polymorphism/restrictionPotential for molecular mimicry or autoimmunity
06

Interacting drugs

Q-Vax

2 more in the full profile.

07

Biomarkers

Interferon-gamma (IFN-gamma) releaseELISpot responseT-cell proliferationMHC multimer stainingInterferon-gamma release assay (IGRA)

Beyond the preview

Go deeper on Coxiella burnetii peptide epitopes bound to Major Histocompatibility Complex (MHC) molecules (C. burnetii peptide-MHC complexes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coxiella burnetii peptide epitopes bound to Major Histocompatibility Complex (MHC) molecules (C. burnetii peptide-MHC complexes).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call